Tragacanth gum
Based on 1 Customer Validation
Tragacanth gum is an orally active anionic composite polysaccharide and multifunctional biomaterial. Tragacanth gum exhibits biocompatibility, mucoadhesion and renoprotective effects, and effectively promotes wound closure and tissue healing. Tragacanth gum can be isolated from Astragalus gummifer. Tragacanth gum acts as an emulsifier and drug delivery carrier, and is also widely used in fields such as 3D scaffolds, tissue engineering and green nanoparticle preparation. High doses of Tragacanth gum may induce reversible forestomach squamous epithelial hyperplasia in mice, but show no mutagenic or carcinogenic activity. Tragacanth gum is commonly used in studies related to diseases including systemic candidiasis, rheumatoid arthritis and osteosarcoma.
For research use only. We do not sell to patients.
- CAS No.: 9000-65-1
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Iron-crosslinked deesterified Tragacanth gum gel microspheres support the adhesion of L929 fibroblasts and show no toxicity to HeLa, HepG2 and L929 cell lines[1].
Calcium alginate composite microspheres containing Tragacanth gum (25-50% w/w) enhance the viability, proliferation, osteogenic differentiation level, and expression of angiogenic markers of MG-63 osteoblasts compared with calcium alginate microspheres[1].
GPTMS-conjugated Tragacanth gum composite scaffolds support the proliferation and differentiation of MG-63 osteoblasts[1].
Bacterial cellulose/keratin electrospun nanofibers containing Tragacanth gum enhance the adhesion and proliferation capacities of L929 fibroblasts[2].
Calcium alginate microspheres containing Tragacanth gum (25-50 (w/v)) enhance the viability, proliferation and differentiation of encapsulated MG-63 osteocytes, and upregulate HIF-1α expression to strengthen pro-angiogenic activity[2].
Collagen hydrogels containing Tragacanth gum (25 mg/mL; 7-21 d) promote osteogenic differentiation of human adipose-derived mesenchymal stem cells by increasing ALP activity, calcium deposition, and the expression of osteogenesis-related genes[2].
Poly (vinyl alcohol)/tragacanth gum/Polycaprolactone hybrid nanofiber scaffolds support the growth and proliferation of NIH 3T3 fibroblasts[2].
Tragacanth gum exhibits antibacterial activity against Escherichia coli and Staphylococcus aureus, and shows no significant toxicity to human fibroblasts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human adipose-derived mesenchymal stem cells (h-ASCs)
-
Concentration:25 mg/mL
-
Incubation Time:7, 14, 21 days
-
Result:Showed no cytotoxicity to h-ASCs.
Increased alkaline phosphatase (ALP) activity significantly at 7, 14, and 21 days compared to controls.
Increased calcium content and deposition significantly at 7, 14, and 21 days compared to controls.
Up-regulated expression of osteogenic-related genes (Runx2, collagen type 1, osteonectin, osteocalcin) significantly at 7, 14, and 21 days compared to controls.
Oral AmpB-loaded TG-AA hydrogels effectively treat systemic candidiasis in male albino mice with no observed liver or kidney toxicity[1].
Topical tragacanth gum application (topical; single treatment period) achieves 90% closure of full-thickness dorsal wounds in male rats after 7 days[1].
Tragacanth gum (2:1 PCL/GT mass ratio, with 3% curcumin loading; implantation directly onto the wound site) enhances full-thickness diabetic skin wound healing in rats, improving wound closure and histological regenerative markers[2].
Tragacanth gum (0.625-5.0% dietary concentration; dietary; ad libitum daily; 13 weeks) causes only slight, biologically unimportant plasma GGT elevations and dose-related, male-specific, nonneoplastic squamous-cell hyperplasia of the forestomach, with no other meaningful toxic effects when administered orally to B6C3F1 mice for 13 weeks[3].
Tragacanth gum (5.0% dietary concentration; dietary; ad libitum daily; up to 48 weeks) induces only transient, reversible squamous-cell hyperplasia of the forestomach with no meaningful toxic or proliferative effects, and its overall oral toxicity is negligible when administered orally to male B6C3F1 mice for up to 48 weeks[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbit[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; single dose
-
Result:Achieved a maximum plasma concentration of 271.47 ng/mL (vs.
114.87 ng/mL for free AmpB solution).
Extended circulation time to reach peak concentration (4 hours vs.
2 hours for free drug).
-
Animal Model:Diabetic rats[2]
-
Dosage:2:1 PCL/GT mass ratio, with 3% curcumin loading
-
Administration:implantation directly onto the wound site
-
Result:Enhanced wound closure observed at 5, 10, and 15 days post-surgery compared to untreated controls.
Improved granulation tissue formation, epithelial regeneration, angiogenesis, and collagen deposition in treated wounds.
Chemical Information
-
CAS No. 9000-65-1
-
Appearance Solid
-
Color White to light yellow
-
SMILES
[Tragacanth gum]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
H2O : ≥ 20 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nazemi Z, et al. A review on tragacanth gum: A promising natural polysaccharide in drug delivery and cell therapy. Int J Biol Macromol. 2023;241:124343. [Content Brief]
[2]. Taghavizadeh Yazdi ME, et al. Gum Tragacanth (GT): A Versatile Biocompatible Material beyond Borders. Molecules. 2021;26(6):1510. Published 2021 Mar 10. [Content Brief]
[3]. Hagiwara A, et al. Oral toxicity study of tragacanth gum in B6C3F1 mice: development of squamous-cell hyperplasia in the forestomach and its reversibility. J Toxicol Environ Health. 1991;34(2):207-218. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tragacanth gum Related Classifications
HY-W250121 Related Classifications
Powered by Bioz